Syngene acquires first US biologics facility for $36.5 million
Overall investment in the US facility is estimated around US$50 million
Overall investment in the US facility is estimated around US$50 million
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
USFDA inspection at Alembic Pharma's Bioequivalence facility
ANVIMO will be available in dosages of 240 mg and 480 mg
Melicica has potential applications in skin repair, scar and acne-prone skin care, tone evening and brightening, texture improvement, baby care, sensitive skin solutions, post-procedure recovery and stretch mark care
Carson brings with him over two decades of experience in Communications, Public Affairs, and Sustainability
Subscribe To Our Newsletter & Stay Updated